Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
16
BIVI Quote, Financials, Valuation and Earnings
Last price:
$1.15
Seasonality move
:
9.69%
Day range:
$1.13 - $1.17
52-week range:
$1.10 - $25.76
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.09x
Volume:
121.9K
Avg. volume:
87.1K
1-year change:
-94.2%
Market cap:
$2.2M
Revenue:
--
EPS (TTM):
-$7.51
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BIVI
BioVie, Inc.
|
-- | -$0.81 | -- | -82.21% | $12.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.37 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BIVI
BioVie, Inc.
|
$1.16 | $12.00 | $2.2M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.64 | $0.85 | $710.7M | 9.47x | $0.80 | 0% | 10.96x |
|
NNVC
NanoViricides, Inc.
|
$1.13 | $6.50 | $20.3M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.78 | $2.00 | $644.5K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.21 | $7.00 | $7.1M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BIVI
BioVie, Inc.
|
1.32% | 3.290 | 9.43% | 15.19x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.780 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | 0.905 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.522 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BIVI
BioVie, Inc.
|
-$57.3K | -$5.3M | -84.85% | -89.06% | -- | -$3M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
BioVie, Inc. vs. Competitors
-
Which has Higher Returns BIVI or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to BioVie, Inc.'s net margin of -255.85%. BioVie, Inc.'s return on equity of -89.06% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital BIVIBioVie, Inc.-- -$0.98 $25.3M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About BIVI or NBY?
BioVie, Inc. has a consensus price target of $12.00, signalling upside risk potential of 934.48%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.93%. Given that BioVie, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe BioVie, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIVIBioVie, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is BIVI or NBY More Risky?
BioVie, Inc. has a beta of 0.362, which suggesting that the stock is 63.808% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock BIVI or NBY?
BioVie, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. BioVie, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIVI or NBY?
BioVie, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. BioVie, Inc.'s net income of -$5.1M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, BioVie, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie, Inc. is -- versus 10.96x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIVIBioVie, Inc.-- -- -- -$5.1M NBYNovaBay Pharmaceuticals, Inc.10.96x 9.47x $521K -$1.3M
-
Which has Higher Returns BIVI or NNVC?
NanoViricides, Inc. has a net margin of -- compared to BioVie, Inc.'s net margin of --. BioVie, Inc.'s return on equity of -89.06% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital BIVIBioVie, Inc.-- -$0.98 $25.3M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About BIVI or NNVC?
BioVie, Inc. has a consensus price target of $12.00, signalling upside risk potential of 934.48%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 475.22%. Given that BioVie, Inc. has higher upside potential than NanoViricides, Inc., analysts believe BioVie, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIVIBioVie, Inc.1 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is BIVI or NNVC More Risky?
BioVie, Inc. has a beta of 0.362, which suggesting that the stock is 63.808% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.439%.
-
Which is a Better Dividend Stock BIVI or NNVC?
BioVie, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIVI or NNVC?
BioVie, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. BioVie, Inc.'s net income of -$5.1M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, BioVie, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIVIBioVie, Inc.-- -- -- -$5.1M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns BIVI or OGEN?
Oragenics, Inc. has a net margin of -- compared to BioVie, Inc.'s net margin of --. BioVie, Inc.'s return on equity of -89.06% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital BIVIBioVie, Inc.-- -$0.98 $25.3M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About BIVI or OGEN?
BioVie, Inc. has a consensus price target of $12.00, signalling upside risk potential of 934.48%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 155.36%. Given that BioVie, Inc. has higher upside potential than Oragenics, Inc., analysts believe BioVie, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIVIBioVie, Inc.1 0 0 OGENOragenics, Inc.1 0 0 -
Is BIVI or OGEN More Risky?
BioVie, Inc. has a beta of 0.362, which suggesting that the stock is 63.808% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.
-
Which is a Better Dividend Stock BIVI or OGEN?
BioVie, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIVI or OGEN?
BioVie, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. BioVie, Inc.'s net income of -$5.1M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, BioVie, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIVIBioVie, Inc.-- -- -- -$5.1M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns BIVI or PTN?
Palatin Technologies has a net margin of -- compared to BioVie, Inc.'s net margin of --. BioVie, Inc.'s return on equity of -89.06% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BIVIBioVie, Inc.-- -$0.98 $25.3M PTNPalatin Technologies-- -- -- -
What do Analysts Say About BIVI or PTN?
BioVie, Inc. has a consensus price target of $12.00, signalling upside risk potential of 934.48%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than BioVie, Inc., analysts believe Palatin Technologies is more attractive than BioVie, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIVIBioVie, Inc.1 0 0 PTNPalatin Technologies0 0 0 -
Is BIVI or PTN More Risky?
BioVie, Inc. has a beta of 0.362, which suggesting that the stock is 63.808% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock BIVI or PTN?
BioVie, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIVI or PTN?
BioVie, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. BioVie, Inc.'s net income of -$5.1M is higher than Palatin Technologies's net income of --. Notably, BioVie, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIVIBioVie, Inc.-- -- -- -$5.1M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns BIVI or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to BioVie, Inc.'s net margin of --. BioVie, Inc.'s return on equity of -89.06% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital BIVIBioVie, Inc.-- -$0.98 $25.3M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About BIVI or TOVX?
BioVie, Inc. has a consensus price target of $12.00, signalling upside risk potential of 934.48%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3227%. Given that Theriva Biologics, Inc. has higher upside potential than BioVie, Inc., analysts believe Theriva Biologics, Inc. is more attractive than BioVie, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIVIBioVie, Inc.1 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is BIVI or TOVX More Risky?
BioVie, Inc. has a beta of 0.362, which suggesting that the stock is 63.808% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.
-
Which is a Better Dividend Stock BIVI or TOVX?
BioVie, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIVI or TOVX?
BioVie, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. BioVie, Inc.'s net income of -$5.1M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, BioVie, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIVIBioVie, Inc.-- -- -- -$5.1M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
